Meeting the needs of rare disease patients: Improved access to specialty pharmaceuticals, gene and cell therapies
Specialty carve outs that move specialty drugs away from traditional prescription drug management to a pharmacy benefit administrator (PBA) or specialty administrator will continue and likely to provide cost savings.